← Back to Home

SonoThera

Private
#Genetic Medicine#Liver Diseases (Hemophilia A and B)#Lysosomal Storage Disorders#Central Nervous System Gene Therapy#Non-Viral Gene Delivery

SonoThera is a biotechnology company developing non-viral, ultrasound-based gene therapies. Its platform uses microbubble-mediated focused ultrasound to deliver DNA, RNA, and other nucleic acid payloads directly to target tissues, eliminating the immunogenicity and packaging-size limitations of viral vectors.

Company Info

Sector: Biotechnology / Gene Therapy (Non-Viral)
Headquarters: South San Francisco, California, USA
Founded: 2019
Website: www.sonothera.com/
Funding Round: Series B (June 2026)
Total Funding: $200M+ (cumulative)

Funding & Investor Relations

Notable Investors

  • Bayer Pharma
  • Roche Venture Fund
  • Bristol-Myers Squibb
  • Ginkgo Bioworks
  • ARCH Venture Partners
  • Khosla Ventures

IPO Outlook / Plans

None publicly disclosed; well-funded private biotech.

Upcoming Milestones & Key Dates

Late 2026 / 2027
Regulatory

SN21-001 IND filing for hemophilia A

Q4 2026
Clinical Trial

First preclinical proof-of-concept data for CNS program

Clinical Development Pipeline

SN21-001

Target: Factor VIII gene delivered via ultrasound-mediated gene therapy
Hemophilia A
Preclinical
Phase 1
Phase 2
Phase 3
Approved

SN21-002

Target: Factor IX gene delivered via ultrasound-mediated gene therapy
Hemophilia B
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Undisclosed CNS program

Target: Ultrasound-mediated delivery to CNS
CNS genetic disorders
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Dr. Kenneth Greenberg

Co-Founder and Chief Executive Officer

Dr. Steve Feinstein

Co-Founder and Chief Scientific Officer

Dr. Michael Davidson

Co-Founder and Executive Chairman

Careers & Job Openings

See all open roles

Multiple Departments
See careers page
Apply Now →